Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma.

Autor: Santos VE; Division of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil. Electronic address: victorespinheira@gmail.com., da Costa WH; Division of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil; National Institute for Science and Technology in Oncogenomics and Therapeutic Innovation, São Paulo, Brazil., Bezerra SM; Division of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil., da Cunha IW; Division of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil; National Institute for Science and Technology in Oncogenomics and Therapeutic Innovation, São Paulo, Brazil.; Department of Pathology, Rede D'Or-São Luiz, São Paulo, Brazil., Nobre JQC; Division of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil., Brazão ES Jr; Division of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil., Meduna RR; Division of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil., Rocha MM; Division of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil., Fornazieri L; Division of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil., Zequi SC; Division of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil; National Institute for Science and Technology in Oncogenomics and Therapeutic Innovation, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: Clinical genitourinary cancer [Clin Genitourin Cancer] 2021 Aug; Vol. 19 (4), pp. 339-345. Date of Electronic Publication: 2021 Mar 17.
DOI: 10.1016/j.clgc.2021.03.003
Abstrakt: Purpose: To evaluate the prognostic impact of immunohistochemical expression of SETD2 in patients with clear cell renal cell carcinoma (ccRCC).
Patients and Methods: A total of 662 patients with primary or metastatic ccRCC were evaluated. Two genitourinary pathologist reviewed all of the cases for uniform reclassification and determined the selection of the most representative tumor areas for construction of the tissue microarray (TMA).
Results: SETD2 nuclear staining showed that 101 areas (15.3%) had negative expression, and 561 areas (84,7%) had positive expression of SETD2. The protein expression of SETD2 was associated with clinical stage (P < .001), pathological stage (P < .001), tumor size (P < .001), perinephric fat invasion (P < .001), Eastern Cooperative Oncology Group status (P = .004), surgery type (P < .001), International Society of Urologic Pathologists grade (P < .001), and tumor necrosis (P < .001). SETD2 influenced disease-specific survival (DSS) and overall survival (OS). DSS rates in patients with positive and negative expression of SETD2 were 90.2% and 58.4%, respectively (P < .001). OS rates in patients with positive and negative expression of SETD2 were 87% and 55.4%, respectively (P < .001). In a multivariate Cox analysis, low SETD2 expression was an independent predictor of DSS (hazard ratio [HR], 1.690; 95% confidence interval [CI], 1.0582.700; P = .031) and OS (HR, 1.641; 95% CI, 1.039-2.593; P = .037).
Conclusion: Our study showed that the negative expression of SETD2 was associated with a worse prognosis, and it was an independent predictor of survival in patients with ccRCC. We believe that the protein expression of SETD2 is an important biomarker in the management of patients with ccRCC.
(Copyright © 2021. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: